Type 2 diabetic mellitus
Conditions
Interventions
Study group:smaglutide
Study group:Intensive Lifestyle Intervention
Control Group:metformin
Control Group:Intensive Lifestyle Intervention
Study group :chiglitazar
Sponsors
Affiliated Hospital of Southwest Medical University
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Male or female aged 20-70 years with BMI >= 25 kg/m2; 2. Diagnosed with type 2 diabetes within 6 years; 3. During screening, HbA1c >= 6.5% and <= 10% in the absence of hypoglycemic drugs or <= 10% in metformin monotherapy; 4. Be able and willing to sign written informed consent and abide by the study protocol.
Exclusion criteria
Exclusion criteria: 1. Within 3 months before signing informed consent, the researchers assessed the following cardiovascular diseases: myocardial infarction, cardiac surgery, or angioplasty or percutaneous coronary angioplasty (coronary artery bypass grafting), unstable angina pectoris, heart failure, unstable New York heart association (NYHA) class IV for congestive heart failure, transient ischemic attack or severe cerebrovascular disease, unstable or before diagnosis of arrhythmia; 2. Received any other hypoglycemic agents other than metformin during the 30 days prior to enrollment or during the 5 study drug half-lives; 3. Weight loss of more than 5kg within 6 months; 4. Pregnant women with positive pregnancy tests, women who wished to become pregnant during the study period, women who were breastfeeding, or women of childbearing age did not use a highly effective and medically proven method of contraception; 5. History of acute complications of diabetes within 30 days (e.g., ketoacidosis, hyperglycemic hyperotonic state) or diabetes insipidus; 6. A history of alcohol, drug abuse or other conditions that may reduce study or medication compliance within 3 months; 7. Within 30 days prior to the use of the drug in this study, they had taken the study drug in another clinical trial or participated in another clinical trial (receiving drug intervention or during the follow-up observation period); 8. Clinically significant liver biliary system diseases, such as chronic active hepatitis with/without severe liver insufficiency. ALT or AST > 3 times the upper limit of normal, or total bilirubin > 34.2 µmol/L( > 2 mg/dL); 9. Severe renal impairment or end-stage renal disease (eGFR < 45 mL/min/1.73 m2); 10. Had bariatric surgery or other gastrointestinal surgery within 2 years that resulted in chronic malabsorption; 11. Had a history of malignant tumor or thyroid cancer within 5 years of the visit; 12. Known immunodeficiency, such as organ transplant or acquired immune deficiency syndrome (AIDS) diagnosis; 13. A history of secondary fractures due to severe osteoporosis; 14. Signed informed consent. Is currently receiving systemic steroid therapy, or has adjusted thyroid hormone medication within 6 weeks, or has an uncontrolled endocrine disease other than type 2 diabetes; 15. Patients were treated with sibutramine, phentermine, orlistat, rimonabant, benzyfatamine, amphiradone, methylamphetamine, and benzometholine within 30 days of follow-up; 16. Currently (or in the past 3 months) participating in an organized weight loss program; 17. Malignant diseases of the blood system or other diseases causing lysis or destruction of red blood cells (e.g., malaria, babesiosis); 18. Take any other study drug within 30 days prior to enrollment or during 5 study drug half-lives. 19. In the investigator's judgment, subjects are unable to comply with the study protocol requirements or have any serious medical or psychiatric condition that could affect the evaluation of efficacy and safety data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycosylated hemoglobin; | — |
Countries
China
Contacts
Public ContactXu Yong
Affiliated Hospital of Southwest Medical University
Outcome results
None listed